Major changes at US FDA, with new posts and appointments

19 July 2011

The world of FDA regulation is changing rapidly and, in an effort to keep current, US Food and Drug Administration Commissioner Margaret Hamburg has announced a major reorganization “The structure of the Office of the Commissioner that I inherited was created in 1970, when the FDA consisted of three centers and a field office,” Dr Hamburg said in an e-mail to agency staff.

“By 2011, we had grown to seven centers, and a Commissioner’s Office with more than 1,600 staff. Over the years, as Congress created new programs that cut across center responsibilities, those programs were placed by default in the Office of the Commissioner. The new organizational alignments more accurately reflect the agency’s responsibilities, subject matter expertise and mandates in an ever more complex world, where products and services do not fit into a single category,” she stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology